# Angeliq Regulatory Post Marketing Surveillance

> **NCT01064453** · — · COMPLETED · sponsor: **Bayer** · enrollment: 4078 (actual)

## Conditions studied

- Postmenopausal Period
- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** E2/DRSP (Angeliq, BAY86-4891)

## Key facts

- **NCT ID:** NCT01064453
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 4078 (ACTUAL)
- **Last updated:** 2013-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064453, "Angeliq Regulatory Post Marketing Surveillance". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01064453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*